Madrigal Pharmaceuticals completes merger with Synta
Madrigal Pharmaceuticals announced the completion of its merger with Synta Pharmaceuticals Corp. The combined company has more than $40 million in cash to advance its research and development efforts, including the clinical development of MGL-3196, Madrigal’s lead product candidate. July 22, 2016